Back

Empagliflozin versus dapagliflozin in heart failure

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heart failure therapy across the spectrum Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Kasper Bonnesen

Copenhagen University Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Early diagnosis of Wild-type Transthyretin Amyloidosis Cardiomyopathy by optimized screening of patients undergoing Carpal Tunnel Syndrome Surgery (CACTuS II)
Mrs S. Fensman (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Home-based rehabilitation in patients with chronic heart failure after acute decompensation: primary results of the PILOT-CRHF trial
Doctor A. Reuser (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
Efficacy of early angiotensin receptor/neprilysin inhibition in post-myocardial infarction patients: a meta-analysis of randomized controlled trials
Associate Professor C. Hsu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Remote rapid titration of heart failure therapies
Doctor A. Abdel-Gadir (London, GB)
Abstract Slides Video
Presentation thumbnail
Short- and long-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure
Doctor V. Bytyqi (Erlangen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure therapy across the spectrum

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study
thumbnail
Congress Presentation
Comparison of dapagliflozin 10 mg versus empagliflozin 10 mg in heart failure patients without type 2 diabetes mellitus on top of triple guideline-directed medical therapy
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources